General Information of Drug (ID: DMGB32Z)

Drug Name
PF-06427878 Drug Info
Indication
Disease Entry ICD 11 Status REF
Cardiovascular disease BA00-BE2Z Phase 1 [1]
Hyperlipidaemia 5C80 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMGB32Z

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vitamin B3 DMQVRZH Chronic renal failure GB61.Z Approved [3]
ARI-3037MO DM9LNXS Cardiovascular disease BA00-BE2Z Phase 2 [4]
PF-06865571 DMZE3GK Non-alcoholic steatohepatitis DB92.1 Phase 2 [5]
PMID25470667-Compound-Figure4-1A DMMVQW8 N. A. N. A. Patented [6]
PMID25470667-Compound-roselipins DMCF2G7 N. A. N. A. Patented [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Diacylglycerol O-acyltransferase 2 (DGAT2) TTRHEQ4 DGAT2_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT02208284) A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects. U.S. National Institutes of Health.
3 Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
4 2011 Pipeline of Arisaph Pharmaceuticals.
5 Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis. J Med Chem. 2022 Nov 24;65(22):15000-15013.
6 Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.